Friedreich Ataxia

Overview

Friedreich Ataxia (FA) is a rare hereditary neurodegenerative disease characterized by progressive loss of coordination (ataxia), muscle weakness, and heart disease. It is the most common inherited ataxia, affecting approximately 1 in 40,000 people in the United States.^1Citation The condition primarily affects the nervous system and heart, leading to significant disability over time. ^1Citation

Introduction

Friedreich Ataxia is an autosomal recessive genetic disorder caused by mutations in the FXN gene (also known as the frataxin gene), which provides instructions for producing the protein frataxin. Frataxin is essential for normal mitochondrial function, particularly in tissues that require high energy output such as the heart, spinal cord, and cerebellum.^2Citation

The disease was first described by Nikolaus Friedreich, a German physician, in 1863. It remains one of the most common hereditary ataxias worldwide and disproportionately affects individuals of European, Middle Eastern, South Asian, and North African ancestry.^1Citation ^3Citation

Disease Mechanism Flowchart

flowchart TD
    A["FXN Gene GAA Repeat Expansion"]  -->  B["Frataxin Deficiency"]
    B  -->  C["Iron-Sulfur Cluster Biosynthesis Defect"]
    C  -->  D["Mitochondrial Iron Accumulation"]
    D  -->  E["Oxidative Stress"]
    E  -->  F["Respiratory Chain Dysfunction"]
    F  -->  G["ATP Depletion"]
    G  -->  H["Dorsal Root Ganglion Degeneration"]
    G  -->  I["Cardiomyocyte Dysfunction"]
    H  -->  J["Sensory Ataxia"]
    I  -->  K["Hypertrophic Cardiomyopathy"]
    J  -->  L["Friedreich Ataxia"]
    K  -->  L
    
    style A fill:#3b1114
    style L fill:#3a3000999

Genetics and Pathophysiology

Genetic Cause

Friedreich Ataxia is caused by a GAA trinucleotide repeat expansion in the FXN gene located on chromosome 9q13.^3Citation Normal individuals have 5-33 GAA repeats, while affected individuals have 66 to over 1,000 repeats.^1Citation This expansion leads to reduced expression of frataxin protein through a mechanism involving chromatin condensation and transcriptional repression.

Frataxin Protein Function

Frataxin is a mitochondrial protein critical for iron-sulfur cluster (Fe-S) assembly, a process essential for the function of numerous enzymes involved in energy production, DNA repair, and oxidative stress response.

The deficiency of frataxin leads to: ^4Citation

Impaired mitochondrial respiratory chain function
Increased oxidative stress
Iron accumulation in mitochondria
Dysregulated iron metabolism
Progressive neuronal degeneration, particularly in the dorsal root ganglia, cerebellum, and spinal cord

Genotype-Phenotype Correlation

The length of the GAA repeat expansion correlates with disease severity and age of onset. Individuals with fewer than 300 repeats typically have later onset (after age 25), while those with more than 1,000 repeats often experience earlier onset and more severe disease progression.^4Citation [^6]

Clinical Features

Core Symptoms

The hallmark symptom of Friedreich Ataxia is progressive ataxia—Loss of coordination affecting gait, balance, and fine motor control. Clinical features include:[^6] [^7]

Neurological Manifestations
- Progressive gait and limb ataxia
- Dysarthria (slurred speech)
- Loss of deep tendon reflexes
- Decreased vibration sense and proprioception
- Muscle weakness, particularly in the lower extremities
- Spasticity and muscle stiffness
- Scoliosis (curvature of the spine)
Cardiac Involvement
- Hypertrophic cardiomyopathy (thickening of the heart muscle)
- Arrhythmias
- Heart failure in advanced disease
Systemic Manifestations
- Diabetes mellitus (in approximately 10-30% of patients)
- Hearing loss and visual impairment
- Fatigue and exercise intolerance

Disease Variants

Classic Friedreich Ataxia: Onset between ages 5-15, most common form
Late-Onset Friedreich Ataxia (LOFA): Onset between ages 26-39
Very Late-Onset Friedreich Ataxia (VLOFA): Onset after age 40
Acadian Variant: Milder form seen in French-Canadian populations

Diagnosis

Clinical Diagnosis

Diagnosis is based on clinical examination findings including:[^7] [^8]

Progressive ataxia with onset before age 25
Absence of deep tendon reflexes in the lower limbs
Loss of vibration sense and proprioception
Muscle weakness
Family history (autosomal recessive inheritance)

Genetic Testing

Confirmatory genetic testing for GAA repeat expansion in the FXN gene gene is the gold standard for diagnosis. Testing can also identify carriers (heterozygotes) with 34-66 repeats.^1Citation [^9]

Additional Diagnostic Tests

Electrocardiogram (ECG) and echocardiogram: To assess cardiac involvement
Nerve conduction studies: May show sensory axonal neuropathy
MRI of the brain and spinal cord: May show atrophy of the cervical spinal cord and cerebellum

Treatment and Management

FDA-Approved Therapy

In February 2023, the U.S. Food and Drug Administration approved omaveloxolone (marketed as Skyclarys) for the treatment of Friedreich Ataxia in adults and adolescents aged 16 years and older.[^8] This is the first FDA-approved therapy for the disease. [^10]

Omaveloxolone is a Nrf2 activator that works by reducing oxidative stress and improving mitochondrial function. Clinical trials demonstrated improvement in neurological function scores compared to placebo.[^9]

Symptomatic Management

Physical Therapy

Balance and gait training
Strengthening exercises
Stretching to reduce spasticity
Fall prevention strategies

Occupational Therapy

Adaptive equipment for daily activities
Home modifications for safety

Speech Therapy

Exercises to improve articulation
Communication aids for advanced disease

Cardiac Care

Regular cardiology follow-up
Medication for heart failure and arrhythmias
Pacemaker placement when indicated
Cardiac transplant in severe cases

Diabetes Management

Blood glucose monitoring
Dietary modifications
Insulin therapy when needed

Surgical Interventions

Scoliosis surgery for severe curvature
Cardiac surgery for advanced cardiomyopathy

Experimental Therapies

Several therapeutic approaches are under investigation:[^10]

Gene Therapy: Vectors designed to deliver functional FXN gene gene to patient cells
Frataxin Modulation: Drugs to increase frataxin expression (e.g., interferon gamma)
Antioxidant Therapies: To combat oxidative stress
Iron Chelation Therapy: To address mitochondrial iron accumulation
Cell-Based Therapies: Stem cell approaches for neuronal replacement

Prognosis

The disease typically progresses over 10-20 years, with most individuals requiring wheelchair assistance approximately 10-15 years after symptom onset.[^6] Life expectancy is reduced, primarily due to cardiac complications. However, with modern cardiac care and the new FDA-approved therapy, outcomes are improving.

Late-onset forms (LOFA and VLOFA) generally have a slower rate of progression and better functional outcomes compared to classic Friedreich Ataxia.^1Citation0

Epidemiology

Prevalence: 1 in 40,000 individuals in the United States
Incidence: Approximately 1 in 50,000 live births
Ethnic Distribution: More common in populations of European, Middle Eastern, South Asian, and North African ancestry
Gender Distribution: Equal affect on males and females

Research and Clinical Trials

Multiple clinical trials are ongoing to develop new treatments for Friedreich Ataxia. Research focuses on:

Gene replacement therapies
Small molecules to increase frataxin expression
Mitochondrial protectors
Antioxidant therapies
Symptomatic treatments for cardiac and neurological manifestations

Patients are encouraged to consult ClinicalTrials.gov for information about enrolling in clinical trials.

Spinocerebellar Ataxia
Motor Neuron Disease
Hypertrophic Cardiomyopathy (see Cardiology)
Mitochondrial Disorders
FXN Gene

External Links

Background

The study of Friedreich Ataxia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

Mitochondrial iron overload is associated with lysosomal dysfunction-mediated mitophagy impairment in the heart of Friedreich’s ataxia. (2026 May) - Mitochondrion
A 38-year-old man with unsteadiness and difficulty walking. (2026 Mar 13) - Practical neurology
An Exploration of Vitamin D Deficiency and Clinical Status in Friedreich’s Ataxia Patients in the UK. (2026 Mar 6) - Movement disorders clinical practice
Repeat-associated ataxias in a German patient cohort analysed by targeted parallel long-read sequencing. (2026 Mar 5) - Brain : a journal of neurology
Identification of Biological Subtypes of Friedreich Ataxia with Structural MRI-based Machine Learning. (2026 Mar) - Radiology